FDA approves first plasmid DNA immunotherapy for recurrent respiratory papillomatosis

FDA grants accelerated approval to Voceryq, the first plasmid DNA immunotherapy, for recurrent respiratory papillomatosis; Medline exits the bed market after an FDA early alert; and an Illinois man pleads guilty to $227M Medicare fraud.